Metrics as of 10/16/2026, 08:43 AM (Berlin time), refresh in progress.
Genflow Biosciences Stock
Genflow Biosciences Plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Eric Leire
- Employees
- 5
- Market cap
- £10 M
- IPO
- 18/01/2022
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling…
Genflow Biosciences stock: price history
1D
-2.8%
1W
-1.7%
1M
-13.8%
6M
-22.2%
YTD
-5.4%
1Y
-20.5%
2Y
-4.4%
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~27% weaker price swings than usual
Ask the agents about Genflow Biosciences
Genflow Biosciences stock metrics
P/E
-7.95
P/B
48.42
EV/EBITDA
-8.89
RETURN ON EQUITY
-110.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
54.8%
FLOAT SHARES
325,668,632
AVG. DAILY VOLUME (30D)
3,833,849
Comparable stocks
Frequently asked questions about Genflow Biosciences stock
What does Genflow Biosciences do?
Genflow Biosciences Plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Eric Leire, the company employs around 5 people.
The IPO was on 18/01/2022; the stock trades on LSE under the ticker GENF.L.
When does Genflow Biosciences report next?
Around past earnings, price swings were roughly -27% stronger than usual.
Does Genflow Biosciences pay a dividend?
No, Genflow Biosciences currently does not pay a dividend.
Which stocks are comparable to Genflow Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Genflow Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Genflow Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.